From the Division of Pediatric Gastroenterology, Hepatology and Nutrition, Harvard Medical School and Boston Children's Hospital, Boston, MA.
Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA.
J Pediatr Gastroenterol Nutr. 2023 Nov 1;77(5):623-627. doi: 10.1097/MPG.0000000000003908. Epub 2023 Aug 7.
Helicobacter pylori ( H pylori ) eradication rates have declined globally, stressing the importance of antimicrobial susceptibility testing to inform treatment. Molecular tests such as next-generation sequencing (NGS) provide susceptibility data for the antibiotics used in the treatment of H pylori in a noninvasive, effective, and rapid manner. We obtained stool susceptibility testing using a novel NGS-based analysis and compared results with the current "gold standard" of gastric biopsy culture via agar dilution in 20 pediatric patients with evidence of H pylori in gastric biopsies. Stool NGS-based antimicrobial susceptibility analysis was highly concordant with agar dilution for no resistance (100% agreement), as well as clarithromycin, levofloxacin, and amoxicillin resistance (100%, 67%, and 100% agreement, respectively) but not concordant for metronidazole in our cohort of patients. Future studies involving a larger number of patients and geographical regions are needed to further validate this analysis.
幽门螺杆菌(H pylori)的根除率在全球范围内有所下降,这强调了进行抗菌药物敏感性测试以指导治疗的重要性。分子测试,如下一代测序(NGS),以非侵入性、有效和快速的方式提供治疗 H pylori 所用抗生素的敏感性数据。我们使用一种新的基于 NGS 的分析方法进行粪便药敏测试,并将结果与 20 名经胃活检证实存在 H pylori 的儿科患者的当前“金标准”胃活检培养琼脂稀释法进行比较。粪便 NGS 基于抗菌药物敏感性分析与琼脂稀释法在无耐药性方面高度一致(100%一致),以及克拉霉素、左氧氟沙星和阿莫西林耐药性方面高度一致(分别为 100%、67%和 100%一致),但在我们的患者队列中甲硝唑不一致。需要进行涉及更多患者和地理区域的未来研究来进一步验证这种分析。